AGIO as reported
Agios Pharmaceuticals, Inc. reported $66M of revenue over the trailing twelve months, +78% on the year before. 9 reported series are charted on this page, each one as filed.
$66M
Revenue, trailing twelve months · to Q1 2026 · +78% against the twelve months before
- Net Income
- −$423M
Net Income · −163% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$385M
Free Cash Flow · −4.7% year on year · trailing twelve months to Q1 2026
- Op Margin
- −767%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $66M | +78% | Q1 2026 |
| Net Income | −$423M | −163% | Q1 2026 |
| EPS | −$7.25 | −165% | Q1 2026 |
| Gross Margin | 89% | n/a | Q1 2026 |
| Op Margin | −767% | n/a | Q1 2026 |
| Net Margin | −680% | n/a | Q1 2026 |
| ROE | −14% | n/a | Q1 2026 |
| ROA | −13% | n/a | Q1 2026 |
| Free Cash Flow | −$385M | −4.7% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Agios Pharmaceuticals, Inc. (AGIO) - Revenue & ProfitRevenue & ProfitAgios Pharmaceuticals, Inc. (AGIO)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com